Aadi BioscienceAADI
Market Cap: $47.5M
About: Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.
Employees: 70
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
180% more call options, than puts
Call options by funds: $14K | Put options by funds: $5K
25% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 16
7% more funds holding
Funds holding: 60 [Q1] → 64 (+4) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
8.99% less ownership
Funds ownership: 55.7% [Q1] → 46.71% (-8.99%) [Q2]
36% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 22
48% less capital invested
Capital invested by funds: $32M [Q1] → $16.7M (-$15.3M) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Piper Sandler Joseph Catanzaro 35% 1-year accuracy 9 / 26 met price target | 9%downside $1.75 | Neutral Downgraded | 27 Aug 2024 |